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phrenia who were treated with antipsychotic medications
during their first post-treatment year. Data were drawn
from January 1987 to July 1996. Allowances were made
for titration and changes in therapy. Multiple logistic re-
gression models were used to identify factors affecting ti-
tration success and conformance. OLS regression models
were used to estimate the impact of the PORT conform-
ance on health care costs. RESULTS: Only 16.9% of the
2,567 patients treated with antipsychotic drugs achieved
conformance with PORT recommendations. Fewer than
50% patients achieved titration success on their initial
drugs, and the likelihood of PORT conformance in-
creased with initial dose. Patients who received at least
the minimum therapeutic dose on their first prescription
were 2.9 times more likely to achieve conformance than
patients who were prescribed less than 50% of the mini-
mum dose (P  0.0001). This odds ratio increased to 8.2
for patients treated initially at 3 times minimum dose
(P  0.0001). Patients treated initially with fluphenazine
were more likely to achieve conformance (odds ratio 
1.834, P  .0001), while thioridazine patients were less
likely to conform (0.436, P  0.0228). PORT conform-
ance was not associated with lower total costs ($2,543,
P  0.2453). CONCLUSION: In clinical practice, the
rate PORT conformance was low and conformance did
not significantly reduce total direct health care costs.
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Previous investigations examining healthcare resource
utilization in patient populations have shown mi-
graineurs to consume significantly higher healthcare re-
sources versus non-migraineurs. However, there is a
dearth of healthcare resource utilization data within mi-
graine populations that examine a specific pharmaceuti-
cal’s impact on resource utilization. OBJECTIVE: To
compare healthcare resource and narcotic use in mi-
graineurs prescribed sumatriptan (oral, subcutaneous, or
nasal) versus migraineurs not prescribed sumatriptan.
DESIGN: A review of the 1998 Idaho Medicaid claims
database was performed. METHODS: Migraine patients
greater than four years of age were identified using two
inclusion criteria—physician diagnosed cases identified
by specific ICD-9-CM codes or patients prescribed mi-
graine-specific drugs. Comorbidity was identified using
specific diagnostic categories. Total healthcare resource
utilization, reported in dollars, was the sum amount paid
by Idaho Medicaid for all medications including anti-mi-
graine prescriptions, physician services, hospital services
(outpatient and inpatient), and emergency room services.
Logarithmic transformations were performed on depen-
dent variables. Linear regression modeling was per-
formed to determine predictors of resource utilization.
RESULTS: 498 migraineurs were identified. Patient char-
acteristics, including presence/absence of comorbidity,
showed no differences between the two groups. Mi-
graineurs prescribed sumatriptan had significantly lower
hospital visits (P  0.01), physician visits (P  0.01),
physician service fees (P  0.05), and fees paid for nar-
cotics (P  0.05). Sumatriptan prescription was not a sig-
nificant predictor of total healthcare utilization (P 
0.05), nor of narcotic use (P  0.05). CONCLUSIONS:
While migraine patients have higher healthcare resource
utilization, this study indicated that sumatriptan users
had significantly lower healthcare resource utilization
than non-sumatriptan users. However, we found that
sumatriptan use was not a significant predictor of higher
healthcare resource dollars.
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Results from a recent trial suggest that combination of
nefazodone and Cognitive Behavioral Analysis System of
Psychotherapy (CBASP) is more efficacious than either
modality alone in the treatment of chronic depression.
OBJECTIVES: This analysis examines the relationship
between treatment modality, clinical measures of depres-
sion severity, measures of patient functioning, and eco-
nomic outcomes. METHODS: Outcomes data from the
12-week acute phase of a 12-site trial investigating the
therapeutic efficacy of nefazodone, CBASP and their
combination using symptom and functional metrics are
combined with medical claims data encompassing 1.4
million lives (MarketScan, The MEDSTAT Group) used
to attribute costs to clinical interventions. Economic ben-
efits of treatment are calculated by multiplying patient in-
come and proportional changes in functional capacity.
Modified versions of the Social Adjustment Scale (SAS),
SF-36, and L.I.F.E. are used to determine functional ca-
pacity. RESULTS: Work impairment improved signifi-
cantly for all groups, but is greatest for combination ther-
apy (P  0.02). This pattern is also observed for the
